Indaptus Therapeutics, Inc. (INDP) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 7.55M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $7.55M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $1.50M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $8.51M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $5.83M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $6.16M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $3.89M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $5.79M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $7.38M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $7.30M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $9.74M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $13.36M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $15.96M | (m) | (m) |
| 2023-06-30 | $19.69M | (m) | $12.70M | $6.99M | (m) |
| 2023-03-31 | $21.68M | (m) | $6.81M | $14.88M | (m) |
| 2022-12-31 | $26.43M | (m) | $9.63M | $16.81M | (m) |
| 2022-09-30 | $28.46M | (m) | $6.72M | $21.74M | (m) |
| 2022-06-30 | $33.01M | (m) | $14.26M | $18.75M | (m) |
| 2022-03-31 | $36.18M | (m) | $33.22M | $2.96M | (m) |
| 2021-12-31 | (m) | (m) | $39.13M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $41.86M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $16.99M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $14.67M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $13.80M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |